<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857503</url>
  </required_header>
  <id_info>
    <org_study_id>180102</org_study_id>
    <nct_id>NCT03857503</nct_id>
  </id_info>
  <brief_title>Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)</brief_title>
  <acronym>ReVEAL</acronym>
  <official_title>Radiographic Imaging Validation and EvALuation for Angio iFR (ReVEAL iFR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Volcano Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Volcano Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Philips Angio-iFR medical software device is intended to provide information on the
      functional significance of a coronary artery lesion to provide guidance on diagnostic
      decisions similar to that obtained through invasive measures of iFR and FFR. The software
      application uses the vessel geometry obtained from a coronary angiographic image together
      with a lumped parameter physiological model to provide the associated iFR and FFR estimates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is intended to demonstrate the diagnostic performance of the image-derived
      physiology model using the invasive physiological measures as the reference standard.

      Specific objectives include the following:

      i) Demonstrate the sensitivity and specificity of image-derived iFR and FFR results for
      identifying functionally significant lesions as determined by the corresponding invasive
      measures; ii) Demonstrate the diagnostic agreement of image-derived iFR and FFR estimates
      with the corresponding invasive measures; iii) Demonstrate the diagnostic performance of
      image derived physiology estimate (iFR/FFR) is superior to visual angiographic assessment for
      the identification of functionally significant stenoses as determined by the corresponding
      invasive physiology measures; iv) Demonstrate reproducibility of the image-derived estimate
      for a given operator and across multiple operators for a given lesion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy of the image-derived iFR</measure>
    <time_frame>1 day</time_frame>
    <description>Diagnostic accuracy of the image-derived iFR and FFR estimate for a given lesion compared to the corresponding invasive iFR and FFR values.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">442</enrollment>
  <condition>Cardiac Ischemia</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Stenosis</condition>
  <arm_group>
    <arm_group_label>Coronary Lesion Assessment with iFR</arm_group_label>
    <description>Patients referred for cardiac catheterization for diagnostic and/or treatment purposes will undergo a screening angiogram to assess eligibility. Eligible patients will be those with at least one major epicardial vessel having a lesion of 40-90% diameter stenosis per visual assessment of angiogram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>iFR</intervention_name>
    <description>Patients will undergo standard of care diagnostic coronary angiography using established invasive physiological criteria for iFR and FFR to aid in clinical decision making for coronary revascularization.
Angiograms will be made in at least two projections, and the treating physician will record his/her estimation of stenosis severity.
Resting iFR and Pd/Pa measures will then be made distal to the target lesion; adenosine will be administered, and the FFR measures will be made without moving the wire. An iFR pullback will then be made after hyperemia as abated. Patients will be treated or deferred from treatment based on physician decision aided by the iFR measures.</description>
    <arm_group_label>Coronary Lesion Assessment with iFR</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for cardiac catheterization for diagnostic and/or treatment purposes will
        undergo a screening angiogram to assess eligibility. Eligible patients will be those with
        at least one major epicardial vessel having a lesion of 40-90% diameter stenosis per visual
        assessment of angiogram.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years old

          2. At least 1 de-novo lesion in 1 or more major epicardial vessels of 40-90% angiographic
             stenosis with a reference vessel size ≥2.5mm in the diseased segment by visual
             estimate

          3. Able and willing to provide informed consent

        Exclusion Criteria:

          1. Presenting with an acute coronary syndrome (ACS), or documented ACS within 4 weeks
             prior to the scheduled index procedure

          2. Cardiogenic shock (sustained (&gt;10 min) systolic blood pressure &lt;90 mmHg in absence of
             inotropic support or the presence of an intra-aortic balloon pump)

          3. Presence of cardiac arrhythmias (e.g., atrial fibrillation, AV-block)

          4. Prior cardiac surgery or implant, including CABG, heart transplant, surgical heart
             valve replacement or repair, TAVI/TAVR, presence of an ICD or pacemaker

          5. Target vessel supplied by a left main coronary artery demonstrating any disease
             present (isolated or non-isolated)

          6. Target vessel supplied by right coronary artery demonstrating any ostial disease
             (located immediately at the origin of the coronary vessels from the aorta)

          7. Target vessel with Chronic Total Occlusion (CTO) in the ipsilateral territory or
             target vessel with an untreated CTO in the contralateral territory. Note: if a CTO
             existing in the contralateral territory is successfully opened, the target vessel in
             the contralateral territory can be included following CTO treatment.

          8. Target vessel with severe tortuosity (≥1 bends of 90° or more, or ≥3 or more bends of
             45°- 90° proximal to the diseased segment)

          9. Target vessel with heavy calcification (multiple persisting opacifications of the
             coronary wall visible in more than one projection surrounding the complete lumen of
             the coronary artery at the site of the lesion.)

         10. Target vessel with TIMI flow grade 1 or 0

         11. Target vessel with severe diffuse disease (more than 75% of the length of the segment
             having a vessel diameter of 2mm, irrespective of the presence or absence of a lesion)

         12. Target lesion is at a bifurcation/trifurcation

         13. Target arteries supplying akinetic or severely hypokinetic territories if already
             known based on prior imaging

         14. Target vessel is supplied by major collaterals

         15. Target stenosis associated with myocardial bridge

         16. Any vascular abnormality precluding optimal contrast opacification (e,g, thrombus,
             ulceration)

         17. Severe aortic or mitral valve disease

         18. Known ejection fraction ≤30%

         19. Known severe renal insufficiency (eGFR&lt;30ml/min/1.72m2)

         20. Any fluoroscopic interference that renders the wire position unclear

         21. Contraindication for adenosine or other hyperemic agent (e.g., caffeine ingestion ≤18
             hours, COPD, hypotension, AV block)

         22. Known pregnancy or planning to become pregnant

         23. Participating in another interventional investigational study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Becky Inderbitzen</last_name>
    <phone>+1.858.764.1336</phone>
    <email>becky.inderbitzen@philips.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sheri L Halverson, MPH</last_name>
    <phone>+1.612.248.7734</phone>
    <email>sheri.halverson@philips.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnold Seto</last_name>
      <phone>408-390-7099</phone>
      <email>Arnold.Seto@va.gov</email>
    </contact>
    <investigator>
      <last_name>Arnold Seto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Heart and Vascular/St Anthony's</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Altman</last_name>
      <phone>303-629-2241</phone>
      <email>JAltman@CHVPC.com</email>
    </contact>
    <investigator>
      <last_name>John Altman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelinne Gamberdella</last_name>
      <phone>203-688-4242</phone>
      <email>jacqueline.gamberdella@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Roberts</last_name>
      <phone>954-265-7900</phone>
      <email>jonathanroberts@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Jonathan Roberts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital- West</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Roberts</last_name>
      <phone>954-265-7900</phone>
      <email>jonathanroberts@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Jonathan Roberts</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Habib Samady</last_name>
      <phone>404-805-6582</phone>
      <email>hsamady@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Habib Samady</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Shammas</last_name>
      <phone>563-324-2828</phone>
      <email>shammas@mchsi.com</email>
    </contact>
    <investigator>
      <last_name>Nick Shammas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Joumaa, MD</last_name>
      <phone>313-343-4811</phone>
      <email>Mouhammed.Joumaa@ascension.org</email>
    </contact>
    <investigator>
      <last_name>M Joumaa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic Medical Center</name>
      <address>
        <city>Manchester</city>
        <state>New Hampshire</state>
        <zip>03102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Flynn, MD</last_name>
      <phone>603-669-0413</phone>
      <email>james.flynn@cmc-nh.org</email>
    </contact>
    <investigator>
      <last_name>James Flynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Side Hospital</name>
      <address>
        <city>Bay Shore</city>
        <state>New York</state>
        <zip>11706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Gruberg</last_name>
      <phone>631-968-3016</phone>
      <email>lgruberg@northwell.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Gruberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vijay S Iver, MD, PhD</last_name>
      <phone>716-829-2663</phone>
      <email>vsiyer@buffalo.edu</email>
    </contact>
    <investigator>
      <last_name>Vijay S Iver, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allen Jeremias</last_name>
      <phone>516-562-6790</phone>
      <email>ajeremias@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Allen Jeremias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manesh Patel</last_name>
      <phone>919-724-9118</phone>
      <email>manesh.patel@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Manesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NC Heart &amp; Vascular</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Trader</last_name>
      <phone>919-787-5380</phone>
      <phone_ext>1018564</phone_ext>
      <email>Nicole.trader@unchealth.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert L Jobe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integris Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Chrysant</last_name>
      <phone>405-951-4364</phone>
      <email>gchrysant@mac.com</email>
    </contact>
    <investigator>
      <last_name>George Chrysant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bryn Mawr Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonis Pratsos, MD</last_name>
      <phone>484-337-4386</phone>
      <email>PratsosA@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Antonis Pratsos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonis Pratsos</last_name>
      <phone>215-565-5936</phone>
      <email>PratsosA@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Antonis Pratsos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centennial Heart</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian K Jefferson, MD</last_name>
      <phone>615-515-1900</phone>
      <email>Brian.Jefferson@HCAhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Brian K Jefferson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karim Al-Azizi, MD</last_name>
      <phone>469-800-6300</phone>
      <email>Karim.AlAzizi@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Karim Al-Azizi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unversitatklinikum, Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Constantin Von zur Muehlen</last_name>
      <phone>+ 49 0761-270-34415</phone>
      <email>constantin.vonzurmuehlen@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Constantin Von zur Muehlen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftsklinikum, Koblenz</name>
      <address>
        <city>Koblenz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Waldermar Bojara, MD</last_name>
      <phone>+49 261 499 2551</phone>
      <email>waldemar.bojara@gk.de</email>
    </contact>
    <investigator>
      <last_name>Waldermar Bojara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatklinikum, Mannheim</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefsan Baumann</last_name>
      <phone>+49 621 383 4701</phone>
      <email>stefan.baumann@umm.de</email>
    </contact>
    <investigator>
      <last_name>Baumann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch Krankenhaus, Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexander Becker, MD</last_name>
      <phone>+49 711 8101 6048</phone>
      <email>alexander.becker@rbk.de</email>
    </contact>
    <investigator>
      <last_name>A Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Galway, CRFG</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faisal Sharif, MD</last_name>
      <email>faisal.sharif@nuigalway.ie</email>
    </contact>
    <investigator>
      <last_name>Faisal faisal.sharif@nuigalway.ie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gifu Heart Center</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hitoshi Matsuo, MD</last_name>
      <phone>+81-58-277-2277</phone>
      <email>matsuo@heart-center.or.jp</email>
    </contact>
    <investigator>
      <last_name>H Matsuo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ehime Medical University</name>
      <address>
        <city>Matsuyama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>T Uetani, MD</last_name>
      <phone>999-999-9999</phone>
      <email>t.ue307@gmail.com</email>
    </contact>
    <investigator>
      <last_name>T Uetani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <zip>99999</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takashi Akasaka, MD</last_name>
      <phone>073-441-0621</phone>
      <email>akasat@wakayama-med.ac.jp</email>
    </contact>
    <investigator>
      <last_name>T Akasaka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Piek, MD</last_name>
      <email>j.j.piek@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Jan Piek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis Breda</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martijn Meuwissen</last_name>
      <phone>+31 76 595 41 81</phone>
      <email>martijnmeuwissen@me.com</email>
    </contact>
    <investigator>
      <last_name>Martijn Meuwissen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medische Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Von Birgelen</last_name>
      <phone>+ 31 53 4872000</phone>
      <email>c.vonbirgelen@mst.nl</email>
    </contact>
    <investigator>
      <last_name>C Von Birgelen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krischan Sjauw</last_name>
      <phone>+31 53 48 721 05</phone>
      <email>Krischan.Sjauw@znb.nl</email>
    </contact>
    <investigator>
      <last_name>K Sjauw</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J van Kuijik, MD</last_name>
      <phone>+31 88 320 09 00</phone>
      <email>j.van.kuijk@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>J van Kuijik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud UMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Damman</last_name>
      <phone>+31 6 22 179 330</phone>
      <email>peter.damman@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>P Damman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Léon</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Perez de Prado</last_name>
      <phone>+34 987 237400</phone>
      <phone_ext>42399</phone_ext>
      <email>aperez@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>A Perez de Prado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Escaned, MD</last_name>
      <email>escaned@secardiologia.es</email>
    </contact>
    <investigator>
      <last_name>Javier Escaned, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Basildon Univeristy Hospital</name>
      <address>
        <city>Basildon</city>
        <zip>SS165NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>kare tang</last_name>
      <phone>+441268524900</phone>
      <email>Kare.Tang@btuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Kare Tang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Galasko</last_name>
      <phone>+44 1253 957 850</phone>
      <email>dr.galasko@bfwhospitals.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>D Galasko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth hospital</name>
      <address>
        <city>Bournemouth</city>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Kodoth</last_name>
      <phone>+44 1202 705 414</phone>
      <email>Vivek.Kodoth@rbch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Vivek Kodoth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College of London- Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12OHS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sayan Sen</last_name>
      <phone>+44 20 3313 6758 / 7350</phone>
      <email>sayan.sen@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Sayan Sen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southampton</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Curzen</last_name>
      <email>nick.curzen@uhs.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>N Curzen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

